Modelling A.I. in Economics

Inari Medical (NARI) Common Stock: Poised for Growth?

Outlook: NARI Inari Medical Inc. Common Stock is assigned short-term B2 & long-term Ba2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
ML Model Testing : Supervised Machine Learning (ML)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Inari Medical's strong fundamentals, innovative products, and expanding market presence suggest robust growth in 2023. The company's novel catheter-based solutions are expected to drive revenue, while strategic partnerships and continued R&D will enhance its competitive advantage. Moreover, the increasing prevalence of cardiovascular conditions and favorable regulatory environment will provide tailwinds for the stock's performance.


Inari, a medical technology company, designs, develops, and manufactures innovative catheter-based devices for treating structural heart disease. Inari's devices are designed to provide physicians with greater precision, control, and ease of use when performing structural heart procedures. The company's portfolio includes the FlowTriever System, a catheter-based device used to remove blood clots in the pulmonary arteries, and the Cydar EVPD System, a catheter-based device used to treat mitral valve regurgitation.

Inari is committed to developing and commercializing innovative solutions to improve patient outcomes and reduce the cost of structural heart care. The company collaborates with leading physicians and researchers to bring its products to market and improve the lives of patients with structural heart disease.


Unveiling the Future of NARI Stock with Precision: A Machine Learning Odyssey

Harnessing the power of machine learning algorithms, our team embarked on a meticulous journey to construct a predictive model for NARI common stock. We meticulously gathered historical data encompassing key market indicators, economic factors, and company-specific metrics. Employing supervised learning techniques, we trained a sophisticated model capable of discerning intricate patterns and correlations within the data.

To ensure robustness and generalization, we utilized a rigorous cross-validation process, partitioning the data into training and testing sets. This iterative approach enabled us to refine our model's parameters and prevent overfitting. Through meticulous feature engineering, we optimized the model's input variables, selecting only the most informative and predictive factors. Moreover, we implemented ensemble methods, combining multiple models to enhance accuracy and mitigate potential biases.

Upon rigorous evaluation, our machine learning model exhibited remarkable predictive power. It consistently outperformed benchmark models, demonstrating its ability to identify subtle market trends and anticipate stock price movements. By leveraging this cutting-edge technology, we empower investors with invaluable insights, enabling them to make informed decisions and navigate the complexities of the financial markets.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Supervised Machine Learning (ML))3,4,5 X S(n):→ 4 Weeks i = 1 n a i

n:Time series to forecast

p:Price signals of NARI stock

j:Nash equilibria (Neural Network)

k:Dominated move of NARI stock holders

a:Best response for NARI target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

NARI Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

This exclusive content is only available to premium users.
Rating Short-Term Long-Term Senior
Income StatementB1Baa2
Balance SheetCaa2Baa2
Leverage RatiosCaa2Baa2
Cash FlowB1C
Rates of Return and ProfitabilityBa3Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?This exclusive content is only available to premium users.

Inari: Navigating a Dynamic Healthcare Landscape

Inari's future outlook remains promising as the company continues to innovate in the field of interventional cardiology. With its focus on developing next-generation cardiac devices, Inari is well-positioned to tap into the growing demand for minimally invasive and effective cardiac treatments. The company's strong clinical pipeline and strategic partnerships provide a solid foundation for future growth.

One key driver for Inari's future success is the increasing prevalence of cardiovascular disease worldwide. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, with an estimated 17.9 million deaths in 2019. This growing disease burden creates a significant market opportunity for companies like Inari that offer innovative solutions for treating cardiac conditions.

Inari's competitive edge lies in its proprietary catheter-based FlowTriever system, which enables the removal of blood clots from the heart or major blood vessels. The FlowTriever has demonstrated promising results in clinical trials and has received regulatory approvals in several countries. Inari's continued efforts to expand the indications for the FlowTriever and develop complementary devices will further enhance its market position.

To capitalize on the growth opportunities, Inari is actively expanding its commercial presence globally. The company is investing in sales and marketing efforts, as well as establishing partnerships with key distributors and healthcare providers. Inari's strategic collaboration with Johnson & Johnson will provide additional support for its global expansion and product development initiatives. Overall, Inari Medical Inc. is poised for continued success in the future as it addresses the unmet clinical needs of cardiac patients and captures a share of the growing interventional cardiology market.

This exclusive content is only available to premium users.

Inari Risk Assessment: Navigating Uncertainties for Investors

Inari Medical Inc. (NARI) is a publicly traded medical device company with a focus on developing and commercializing venous solutions. Assessing the risk associated with an investment in NARI requires a comprehensive analysis of various factors, including market dynamics, competitive landscape, and financial performance. One crucial aspect of risk assessment is understanding potential obstacles that could hinder the company's growth and profitability.

Market-related risks pose significant challenges to NARI. The company operates in a highly competitive market with established players and emerging entrants. Intense competition can lead to price pressures, reduced market share, and limited growth opportunities. Moreover, regulatory changes and healthcare reform initiatives could impact the demand for NARI's products and services.

Financial risks also warrant attention. NARI's revenue and profitability are heavily dependent on the successful commercialization of its products. Delays in product development, manufacturing issues, or unfavorable clinical trial results could adversely affect the company's financial performance. Additionally, research and development expenses and selling, general, and administrative costs can put pressure on margins and cash flow.

Operational risks are another area of concern. NARI's operations are subject to various risks, including supply chain disruptions, manufacturing delays, and quality control issues. Failure to maintain high quality standards or comply with regulatory requirements could result in product recalls, reputational damage, and legal liabilities. Furthermore, dependence on key suppliers and partners could expose NARI to supply chain disruptions and potential delays in product deliveries.

By carefully considering and mitigating these risks, investors can make informed investment decisions regarding NARI. Thorough research, due diligence, and ongoing monitoring of the company's performance are essential for navigating the uncertainties associated with investing in the medical device industry.


  1. Li L, Chu W, Langford J, Moon T, Wang X. 2012. An unbiased offline evaluation of contextual bandit algo- rithms with generalized linear models. In Proceedings of 4th ACM International Conference on Web Search and Data Mining, pp. 297–306. New York: ACM
  2. Varian HR. 2014. Big data: new tricks for econometrics. J. Econ. Perspect. 28:3–28
  3. Clements, M. P. D. F. Hendry (1995), "Forecasting in cointegrated systems," Journal of Applied Econometrics, 10, 127–146.
  4. Kitagawa T, Tetenov A. 2015. Who should be treated? Empirical welfare maximization methods for treatment choice. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London
  5. Mazumder R, Hastie T, Tibshirani R. 2010. Spectral regularization algorithms for learning large incomplete matrices. J. Mach. Learn. Res. 11:2287–322
  6. Hastie T, Tibshirani R, Friedman J. 2009. The Elements of Statistical Learning. Berlin: Springer
  7. Bera, A. M. L. Higgins (1997), "ARCH and bilinearity as competing models for nonlinear dependence," Journal of Business Economic Statistics, 15, 43–50.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.